KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Gross Profit (2020 - 2023)

AbCellera Biologics' Gross Profit history spans 4 years, with the latest figure at $6.1 million for Q4 2023.

  • For the quarter ending Q4 2023, Gross Profit fell 69.67% year-over-year to $6.1 million, compared with a TTM value of $27.3 million through Dec 2023, down 94.11%, and an annual FY2024 reading of $16.1 million, down 32.67% over the prior year.
  • Gross Profit for Q4 2023 was $6.1 million at AbCellera Biologics, down from $6.6 million in the prior quarter.
  • The five-year high for Gross Profit was $314.2 million in Q1 2022, with the low at $4.2 million in Q1 2020.
  • Average Gross Profit over 4 years is $66.4 million, with a median of $15.4 million recorded in 2020.
  • Year-over-year, Gross Profit soared 4643.2% in 2021 and then plummeted 97.32% in 2023.
  • Tracing ABCL's Gross Profit over 4 years: stood at $182.4 million in 2020, then fell by 24.62% to $137.5 million in 2021, then crashed by 85.42% to $20.0 million in 2022, then plummeted by 69.67% to $6.1 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Gross Profit are $6.1 million (Q4 2023), $6.6 million (Q3 2023), and $6.2 million (Q2 2023).